Table 1. Pharmacokinetic parameters for the plasma and tumour concentrations of paclitaxel after single i.v. administration of NK105 and PTX to Colon 26-bearing CDF1 mice.

Treatment	Dose (mg kg−1)	C5 min (μg ml−1)	t 1/2 z (h)	AUC0–t (μg h ml−1)	AUC0−inf. (μg h ml−1)	CLtot (ml h kg−1)	Vss (ml kg−1)
Plasma
PTX	50	59.32	0.98	90.2a	91.3	547.6	684.6
PTX	100	157.67	1.84	309.0b	309.0	323.6	812.2
NK105	50	1157.03	5.99	7860.9c	7862.3	6.4	46.4
NK105	100	1812.37	6.82	15 565.7c	15 573.6	6.4	54.8

		Cmax (μg ml−1)	Tmax (h)	t 1/2 z (h)	AUC0–t (μg h ml−1)	AUC0–inf. (μg h ml−1)
Tumour
PTX	50	12.50	2.0	7.02	120.8b	133.0
PTX	100	28.57	0.5	8.06	330.4c	331.0
NK105	50	42.45	24.0	35.07	2360.1c	3192.0
NK105	100	71.09	6.0	73.66	3884.9c	7964.5

i.v.=intravenous; C_5 min=plasma concentration at 5 min; t_1/2z=half-life at the terminal phase; AUC=area under the curve; CL_tot=total body clearance; V_ss=volume of distribution at steady state; T_max=time of maximum concentration; PTX=paclitaxel.

Parameters were calculated from the mean value of three or two mice by noncompartmental analysis.

^aAUC_0-6h.

^bAUC_0–24 h.

^cAUC_0–72 h.